53
DAFTAR PUSTAKA
1. Pepys MB, Hirschfield GM. C-Reactive Protein:A Critical Update. The
Journal Of Clinical Investigation, 2003, Vol.111, p. 1805-1811.
2. Agrawal A, Hammond DJ, and Singh SK,Atherosclerosis-related functions
of C-reactive protein Cardiovasc Hematol Disord Drug Targets. 2010
December 1; 10(4): 235–240.
3. Cushman RM, Emerging Biomarkers for Primary Prevention of
Cardiovascular Disease and Stroke,Inflammation Biomarkers and
Cardiovascular Disease,2009, chapter 3, p;11-15
4. Ridker PM, Hennekens CH,. Buring JE, And Rifai N; C-Reactive Protein
And Other Markers Of Inflammation In The Prediction Of Cardiovascular
Disease In Women; Engl J Med 2000; 342:836.
5.
Isfahan, Diabetes Research and Clinical Practice, N. Eng J Med. 2005;
352; 1685-95.
6. Paffen E, Moniek P.M, C-reactive protein in atherosclerosis: A causal
factor? Cardiovascular Research 2006; 71; 30 – 39
7. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive Protein and
Other Markers of Inflammation in the Prediction of Cardiovascular
Disease in Women, N Engl J Med 2000; 342:836-843
8. Nilsson PM, Gudbjo¨rnsdottir S, Eliasson B, Cederholm J, Hypertension in
diabetes: trends in clinical control in repeated large-scale national surveys
from Sweden, Journal of Human Hypertension 2003; 17; 37–44.
9. Epstein M, Sower JR. Diabetes and Hypertension, Journal of The
American Heart Association. 1992; 19;403-18.
10. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M, Endothelial
Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Medicinal Chemistry, 2009, 16;94-112
11.
Sensitivity C-Reactive Protein In Subjects With Type 2 Diabetes Mellitus
And/Or High Blood Pressure. Arq Bras EndocrinolMetab
54
12. Anand AV, Muneeb M, Divya N, Senthil R, Kapoor MMA, et.al. Clinical
Significance Of Hypertension, Diabetes And Inflammation, As Predictor Of
Cardiovascular Disease. Int J Biol Med Res. 2011; 2(1): 369-373.
13.
In Patients With Diabetes Mellitus.
Dec;30(4):983-97
14.
Of Systolic Blood Pressure With Macrovascular And Microvascular
Complications Of Type 2 Diabetes (Ukpds 36): Prospective Observational
Study,
15. Permana H,. Pengelolaan Hipertensi Pada Diabetes Mellitus Tipe 2. Fk
Unpad, Bandung, 2008.
16. Khera A. Biomarkers In Heart Diseases, Blackwell Publishing..
Massachussetts,1st Edition,2008, p:161-180.
17. Bratawidjaja Kg. Imunologi Dasar. Gaya Baru, Jakarta, ,2006, Ed:7; Hal.
13-15, 391-408.
18. Hegde V, Ching I, Vascular Inflammation: A New Horizon in
Cardiovascular RiskAssessment. In: Gasparyan AY (Ed.). Cardiovascular
Risk Factors, 2012, Chapter 5,P. 103-140.
19. Libby P, Ridker PM, GK. Hansson, Inflammation In Atherosclerosis From
Pathophysiology,Journal Of The American College Of Cardiology, 2009,
Vol. 54, No. 23.
20. Handojo I. Imunoasai Terapan Pada Beberapa Penyakit Infeksi. Airlangga
University Press. Cetakan I. Surabaya, 2004, Hal. 272-285
21. Roche Diagnostic GmbH. CRPHS. Roche diagnostics. Indianapolis. 2011;
p.1-4.
22. International Diabetes Federation. IDF Clinical Guidelines Task Force.
Globa Guideline For Type 2 Diabetes. Brussels, 2005
23. Green FS, Baxter JD, Endokinologi Dasar Dan Klinik,Edisi 4, 2000; Hal
742.
24. Perkumpulan Endokrinologi Indonesia. Konsensus Pengelolaan Dan
Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2006. Pb Perkeni,
Jakarta 2006 : 1 – 47.
25. Groop Lc. Type 2 Diabetes Mellitus: Pathogenesis And Treatment. In
55
26. American Diabetes Association; Diagnosis and Classification of
DiabetesMellitus, Diabetes Care. 2010 Jan; 33(Suppl 1): S62–S69.
27. Lancet, Principles Of Phatogenesis And Therapy. 2005 ; 365: 1333- 34.
28. Bakker Sj, Gans R, Maaten Jc, The Potential Role Of Adeosine In
Pathophysiology Of The Insulin Resistance Syndroma. Atherosklerosis
2001: 155: 283-90.
29. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology,
Diagnosis And Prognostic Implications Of Endothelial Dysfunction. Ann
Med. 2008;40(3):180-96.
30. Hanson Gk ,Inflammation, Atherosclerosis, And Artery Coronary Disease.
N. Eng J Med. 2005; 352; 1685-95).
31. Yang H, Jin X, Lam CW, Yan SK,Oxidative stress and
diabetesmellitus; Clinical Chemistry and Laboratory Medicine , 2011,
Volume 49, Issue 11 Pages 1773–1782
32.
Guidelines for the Management of Hypertension,
33. Yogiantoro, M. Hipertensi Esensial.; Buku Ajar Penyakit Ilmu Penyakit
Dalam. Pusat Penerbitan Ilmu Penyakit Dalam FK UI. Jakarta : Ed 4 34. Beevers G, Lip GYH, O'brien E; The Pathophysiology Of Hypertension ,
Bmj, 2001, Volume 322.
35. Gilbert RE, Jasik M, DeLuise M, O'Callaghan CJ, Cooper ME. Diabetes
and hypertension. In: Australian Diabetes Society position statement.
Medical Journal of Australian 1995; 163: 372-375.
36. Standley PR, Bakir MH, Sowers JR. Vascular insulin abnormalities,
hypertension, and accelerated atherosclerosis:
Jun;21(6 Suppl 3):39-46
37. Inoguchi T, Li P, Umeda F. High Glucose Level And Free Fatty Acid
Stimulate Reactive Oxygen Species Production Through Protein Kinase
C-Dependent Activation Of Nad(P)H Oxidase In Cultured Vascular Cells.
Diabetes. 2000;49:1939-1945.
38. Ridwan M, Gotera W, Pengaruh Insulin Terhadap Fungsi Kardiovaskular; J
56
39. Sowers Jr, Sowers Ps, Peuler Jd. Role Of Insulin Resistance And
Hyperinsulinemia In Development Of Hypertension And Atherosclerosis. J
Lab Clin Metab. 1994;123:647-652.
40. KimJ, MontagnaniM, KohKK,QuonMJ: Reciprocal Relationships Between
Insulin Resistance and Endothelial Dysfunction Molecular and
Pathophysiological Mechanisms ; Circulation. 2006;113:1888-1904.
41. Ramasamy R, Yan SF, Schmidt AM, Receptor for AGE (RAGE): signaling
mechanisms in the pathogenesis of diabetes and its complications, Annals
